Glenmede Trust Co. NA Has $72.63 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Glenmede Trust Co. NA increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 144.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 306,511 shares of the medical research company’s stock after purchasing an additional 180,890 shares during the period. Glenmede Trust Co. NA’s holdings in IQVIA were worth $72,634,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the 3rd quarter valued at approximately $27,000. Park Place Capital Corp acquired a new position in IQVIA during the third quarter valued at approximately $28,000. Versant Capital Management Inc lifted its stake in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at $27,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the 2nd quarter valued at $29,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 1.4 %

IQV opened at $201.24 on Wednesday. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a fifty day moving average of $221.18 and a 200-day moving average of $226.75. The stock has a market cap of $36.53 billion, a PE ratio of 26.41, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analyst Ratings Changes

IQV has been the subject of a number of research reports. The Goldman Sachs Group dropped their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Robert W. Baird decreased their target price on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research note on Friday, November 1st. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, BTIG Research reduced their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.